Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Significance: Poly(ADP-ribose) polymerase (PARP) inhibitors have produced responses in homologous recombination (HR) repair-deficient cancers, such as those with a mutated breast cancer 1, early onset ( BRCA1 ) gene. We have delineated a two-event mechanism of acquired resistance by using a BRCA1 BRCA C-terminal (BRCT) domain-mutated breast cancer cell line, involving heat shock protein (HSP)90-mediated stabilization of the mutant protein coupled with tumor protein p53 binding protein 1 ( TP53BP1 ) gene mutation, which together restore DNA end resection and RAD51 filament formation, critical steps in HR. Similar events may occur in primary BRCA1 -mutated ovarian cancers as cells develop resistance to platinum. The data demonstrate that, even though BRCA1 BRCT domain mutant proteins cannot promote DNA end resection, they retain partial function and can contribute to RAD51 loading and HR. Finally, HSP90 inhibition may prove useful for resensitizing resistant BRCA1 -mutant cancer cells to drug treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · cited 1×
“In particular, BRCA1deficient cell lines are exquisitely sensitive to poly(ADP-ribose) polymerase (PARP) inhibition (5).”
BackgroundInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
HSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502
Mutational Processes Molding the Genomes of 21 Breast Cancers
Nik-Zainal, S., Alexandrov, L. B., Wedge, D. C., Van Loo, P., Greenman, C. D., Raine, K., Jones, D., Hinton, J., Marshall, J., Stebbings, L. A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.024 · Cited by 1,909
53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
Bunting, S. F., Callén, E., Wong, N., Chen, H.-T., Polato, F., Gunn, A., Bothmer, A., Feldhahn, N., Fernandez-Capetillo, O., Cao, L., et al. (2010) · Cell · doi:10.1016/j.cell.2010.03.012 · Cited by 1,671
Association of BRCA1 with Rad51 in Mitotic and Meiotic Cells
Scully, R., Chen, J., Plug, A., Xiao, Y., Weaver, D., Feunteun, J., Ashley, T., & Livingston, D. M. (1997) · Cell · doi:10.1016/s0092-8674(00)81847-4 · Cited by 1,459
Human CtIP promotes DNA end resection
Sartori, A. A., Lukas, C., Coates, J., Mistrik, M., Fu, S., Bartek, J., Baer, R., Lukas, J., & Jackson, S. P. (2007) · Nature · doi:10.1038/nature06337 · Cited by 1,362 · cited 1×
“DNA end resection is dependent on the activities of BRCA1 and CtIP proteins (17, 18).”
BackgroundBouwman, P., Aly, A., Escandell, J. M., Pieterse, M., Bartkova, J., van der Gulden, H., Hiddingh, S., Thanasoula, M., Kulkarni, A., Yang, Q., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1831 · Cited by 1,001
PALB2 is an integral component of the BRCA complex required for homologous recombination repair
Sy, S. M. H., Huen, M. S. Y., & Chen, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811159106 · Cited by 614
Norquist, B., Wurz, K. A., Pennil, C. C., Garcia, R., Gross, J., Sakai, W., Karlan, B. Y., Taniguchi, T., & Swisher, E. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.2980 · Cited by 577
Self-citationCtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle
Yun, M. H., & Hiom, K. (2009) · Nature · doi:10.1038/nature07955 · Cited by 556
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
Jaspers, J. E., Kersbergen, A., Boon, U., Sol, W., van Deemter, L., Zander, S. A., Drost, R., Wientjens, E., Ji, J., Aly, A., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0049 · Cited by 514
Secondary BRCA1 Mutations in BRCA1 -Mutated Ovarian Carcinomas with Platinum Resistance
Swisher, E. M., Sakai, W., Karlan, B. Y., Wurz, K., Urban, N., & Taniguchi, T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0088 · Cited by 457
Self-citationThe Role of BRCA1 in the Cellular Response to Chemotherapy
Kennedy, R. D., Quinn, J. E., Mullan, P. B., Johnston, P. G., & Harkin, D. P. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh312 · Cited by 430
PALB2 Functionally Connects the Breast Cancer Susceptibility Proteins BRCA1 and BRCA2
Zhang, F., Fan, Q., Ren, K., & Andreassen, P. R. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0123 · Cited by 306
BRCA1 Mutation Analysis of 41 Human Breast Cancer Cell Lines Reveals Three New Deleterious Mutants
Elstrodt, F., Hollestelle, A., Nagel, J. H. A., Gorin, M., Wasielewski, M., van den Ouweland, A., Merajver, S. D., Ethier, S. P., & Schutte, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2853 · Cited by 305
BRCA1 RING Function Is Essential for Tumor Suppression but Dispensable for Therapy Resistance
Drost, R., Bouwman, P., Rottenberg, S., Boon, U., Schut, E., Klarenbeek, S., Klijn, C., van der Heijden, I., van der Gulden, H., Wientjens, E., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.014 · Cited by 262
BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity
Shakya, R., Reid, L. J., Reczek, C. R., Cole, F., Egli, D., Lin, C.-S., deRooij, D. G., Hirsch, S., Ravi, K., Hicks, J. B., et al. (2011) · Science · doi:10.1126/science.1209909 · Cited by 244 · cited 1×
“Other studies have demonstrated functionality of N-terminal missense mutations, and knock-in Brca1-deficient mouse models expressing these mutants responded poorly to platinum drugs, mitomycin C, or PARP inhibition (23, 24).”
BackgroundLee, M. S., Green, R., Marsillac, S. M., Coquelle, N., Williams, R. S., Yeung, T., Foo, D., Hau, D. D., Hui, B., Monteiro, A. N. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4563 · Cited by 168
Oplustilova, L., Wolanin, K., Mistrik, M., Korinkova, G., Simkova, D., Bouchal, J., Lenobel, R., Bartkova, J., Lau, A., O’Connor, M. J., et al. (2012) · Cell Cycle · doi:10.4161/cc.22026 · Cited by 163
Detection of Protein Folding Defects Caused by BRCA1-BRCT Truncation and Missense Mutations
Williams, R. S., Chasman, D. I., Hau, D. D., Hui, B., Lau, A. Y., & Glover, J. N. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m310182200 · Cited by 137
Dungey, F. A., Caldecott, K. W., & Chalmers, A. J. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0201 · Cited by 113
Structural Consequences of a Cancer-causing BRCA1-BRCT Missense Mutation
Williams, R. S., & Glover, J. N. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210019200 · Cited by 100
RNF8 Regulates Assembly of RAD51 at DNA Double-Strand Breaks in the Absence of BRCA1 and 53BP1
Nakada, S., Yonamine, R. M., & Matsuo, K. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1057 · Cited by 62
Cited by
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmaña, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,671
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945
“HSP90 may stabilize the BRCT domain of these mutant BRCA1 proteins under PARPi selection pressure (150); the HSP90-stabilized mutant BRCA1 proteins can efficiently interact with PALB2–BRCA2–RAD51, form RAD51 foci, and confer PARPi and cisplatin resistance.”
BackgroundSelf-citationHomologous Recombination and Human Health: The Roles of BRCA1, BRCA2, and Associated Proteins
Prakash, R., Zhang, Y., Feng, W., & Jasin, M. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016600 · Cited by 869
“However, mutations in the BRCT domain often result in destabilization of the mu- tant BRCA1 protein (Williams and Glover 2003; Williams et al. 2003; Lee et al. 2010) and thus impair RAD51 loading despite an intact PALB2interaction domain (Johnson et al. 2013).”
BackgroundPantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A. K., Kothari, A., Wang, D., Visal, T., Li, M. K., Pinto, J., Castrillon, J. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1218 · Cited by 743
Metadata
- Authors
- Johnson, N., Johnson, S. F., Yao, W., Li, Y.-C., Choi, Y.-E., Bernhardy, A. J., Wang, Y., Capelletti, M., Sarosiek, K. A., Moreau, L. A., Chowdhury, D., Wickramanayake, A., Harrell, M. I., Liu, J. F., D’Andrea, A. D., Miron, A., Swisher, E. M., & Shapiro, G. I.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2013-10
- Volume
- 110
- Issue
- 42
- Pages
- 17041-17046
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2073569331
- Cited by
- 265
- References
- 24
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.